MOTS-c
MOTS-c, also written MOTS c, is supplied by White Label Peptides as a lyophilised powder in multi-dose vials, for laboratory and research use, to business buyers only. It sits in our longevity category. Every batch is verified by HPLC and ships with its own Certificate of Analysis.
| Compound | MOTS-c |
|---|---|
| Full name | Mitochondrial Open Reading Frame of the 12S rRNA-c |
| Classification | Metabolic & Longevity Research Peptide |
| Peptide type | Mitochondrial-Derived Peptide |
| Molecular formula | C101H152N28O22S2 |
| Molecular weight | Approximately 2174.6 g/mol |
| Sequence | MRWQEMGYIFYPRKLR |
| Form | Lyophilised powder (vials) or ready-to-use solution (pre-filled pens) |
| Appearance | White to off-white lyophilised powder prior to reconstitution |
| Presentation | Vials: 10 mg. Pre-filled pens: 10 mg, 40 mg |
| Reconstitution | Typically reconstituted using: Bacteriostatic water - Sterile laboratory-grade water |
| Storage | Store refrigerated at 2-8°C in a cool, dry environment away from direct sunlight. Long-term storage may require freezing conditions prior to reconstitution. |
| Also written | MOTS c, MOTS c peptide |
Specification data is provided for identification and procurement. It is not dosing guidance and it is not a claim of any effect.
Evidence and status
- Lab work
- Animal studies
- Human studies
- Approved label
Reviewed 2026-09-02. Regulatory status is stated for procurement and varies by market. It is not legal advice.
Research
What the published literature examined
A substantial mechanistic literature and no clinical one. Work has examined it as a mitochondrial-derived peptide regulating metabolic homeostasis, its requirement for mitofusion in GLUT4 translocation, its role in plasma membrane repair through TRIM72 translocation, its effect on dexamethasone-induced atrophy in human skeletal muscle cells, and its behaviour in ovarian cancer models. A 2023 review states plainly that it has been used infrequently in disease and that no effective method of applying it in the clinic has been developed.
What is not established
Clinical application of any kind. The review literature says so directly rather than by implication. Work in human skeletal muscle CELLS is not work in humans, and the mechanism by which it opposes glucocorticoid-induced atrophy in those cells is described as unexplored. There is no dose, no route and no safety data in people.
What distinguishes MOTS-c
It has the deepest mechanistic literature of any compound in the catalogue with no clinical literature at all, and the two facts are usually presented as one. A long citation list reads as evidence of effect; here it is evidence of interest. The honest summary is that researchers find it interesting and nobody has yet shown it does anything in a person.
Sources
- MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation
- MOTS-c, the most recent mitochondrial derived peptide in human aging and age-related diseases
- Mitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cells
- Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating translocation of TRIM72
- Mitofusion is required for MOTS-c induced GLUT4 translocation
This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.
Specification
About this compound
The specification below is the batch-independent data. Purity and analysis date vary by batch, so they appear on the certificate issued with your order rather than on this page.
What this compound is
MOTS-c in supply terms
MOTS-c takes its name from Mitochondrial Open Reading Frame of the 12S rRNA, denoted c, reflecting the genomic region its sequence is derived from rather than a laboratory synthesis route. As supplied, it is a synthetic peptide reproducing the 16-residue sequence MRWQEMGYIFYPRKLR, with a molecular formula of C101H152N28O22S2 and a molecular weight near 2174.6 g/mol, placing it in the mid-size range for the peptides on this list. It is classed here as a mitochondrial-derived peptide, a category defined by the genetic origin of the sequence rather than by any claim attached to the compound. It is supplied as a lyophilised powder in multi-dose vials at 10mg or 40mg fill weights, in an injectable research format, intended for reconstitution with bacteriostatic water or sterile laboratory-grade water. Store at 2-8C, protected from light, with freezing recommended for stock held longer term ahead of reconstitution. The 40mg option carries roughly four times the peptide content of the 10mg vial for a smaller proportional increase in unit cost, a point worth checking when comparing landed cost per milligram across suppliers offering only the smaller fill.
This section describes the compound as a material. It makes no claim about any effect and is not guidance on use.
What varies by batch
The page identifies the compound. The certificate records the batch.
Purity, method, analysis date and issuing party belong on the batch record rather than in page copy.
| Send the volume you need for MOTS-c and your delivery country. We will quote against it. | Request pricing |
Same category
Also in Longevity
| Compound | Identifier | Presentation |
|---|---|---|
| 5-Amino-1MQ | 42464-96-0 (commonly supplied a... | Vials: 50 mg. Pre-filled pens: ... |
| Epithalon | C14H22N4O9 | Vials: 10 mg. Pre-filled pens: ... |
| FOXO4-DRI | 2460055-10-9 | Vials: 10 mg. Pre-filled pens: ... |
| NAD+ | C21H27N7O14P2 | Vials: 500 mg. Pre-filled pens:... |
| SS-31 | C32H49N9O5 | Vials: 10 mg |
| Thymosin Alpha-1 (TA) | 62304-98-7 | Vials: 5 mg, 10 mg. Pre-filled ... |
Questions
Supply, answered
Is MOTS-c available for private label?
Yes. It can be supplied under your own brand on the vial and the carton, with the Certificate of Analysis issued under your product name.
What is the minimum order quantity?
Set for this compound specifically and confirmed at the enquiry stage, before you commit.
What purity is supplied?
98 percent or higher, verified by HPLC. The certificate issued with your batch carries the actual figure for that batch.
How is it shipped?
As lyophilised powder in multi-dose vials, packed for transit. Delivery in 5 to 7 days once the batch is released.
We already buy MOTS-c. Can you quote against our current volume?
Yes. Send the volume and the delivery country. Pricing is tiered per compound, so the quote reflects what you buy rather than a list price.
Can you supply MOTS-c as a second source?
Yes. Terms are agreed per compound, so you can add MOTS-c without moving anything else you buy elsewhere.
Request pricing for MOTS-c
Indicative volume and delivery country is enough to start. We reply within one working day.